Welcome to our dedicated page for Hikma Pharmaceuticals Plc news (Ticker: HKMPY), a resource for investors and traders seeking the latest updates and insights on Hikma Pharmaceuticals Plc stock.
Hikma Pharmaceuticals Plc (HKMPY) is a global leader in developing generic medicines and emergency treatments, serving healthcare systems across 50+ countries. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's operational milestones, regulatory developments, and market strategies.
Our curated collection offers centralized access to Hikma's financial reports, product launch announcements, and partnership agreements. Track updates across therapeutic innovations, manufacturing expansions, and quality assurance initiatives that reinforce the company's position in global pharmaceuticals.
Key coverage areas include quarterly earnings disclosures, FDA approvals for critical medications like opioid overdose treatments, and strategic collaborations with public health organizations. All content is sourced from verified channels to ensure accuracy and relevance for stakeholders.
Bookmark this page for streamlined monitoring of Hikma's business developments. Combine our news feed with Stock Titan's financial analysis tools to maintain informed perspectives on this London-listed healthcare innovator.
Hikma Pharmaceuticals and Glenmark Specialty announced the US launch of RYALTRIS™, a nasal spray for treating seasonal allergic rhinitis (SAR), approved by the FDA for patients aged 12 and older. This combination therapy relieves nasal and ocular symptoms, offering onset relief in 15 minutes. With 60 million Americans affected by allergic rhinitis, this product addresses a significant unmet need, particularly as many patients report inadequate symptom control. Hikma aims to expand its specialty business in the US through this launch, utilizing its existing salesforce to reach healthcare providers.
Hikma Pharmaceuticals PLC has publicly clarified that it has not engaged in any transaction with Opiant Pharmaceuticals, directly contradicting a prior announcement from PR Newswire. The earlier communication suggested Hikma entered into a commercialization and licensing agreement for OPNT003, Nasal Nalmefene, in Europe and the UK, which Hikma has confirmed is not the case. This statement helps to prevent any potential misinterpretations regarding Hikma's current partnerships and licensing activities.
Hikma Pharmaceuticals has completed its acquisition of Custopharm for an initial $375 million, enhancing its US Injectables portfolio significantly. This acquisition adds 13 approved products and strengthens Hikma's R&D capabilities, bolstering its position as the second-largest supplier of generic sterile injectables in the US. Notable achievements include Custopharm's strong regulatory track record with four first-to-market FDA approvals. The acquisition was approved by the US Federal Trade Commission and positions Hikma for better service delivery to healthcare providers and patients.
Hikma Pharmaceuticals PLC announced that it has received preliminary approval from the US Federal Trade Commission (FTC) for its acquisition of Custopharm Inc. from Water Street Healthcare Partners. This follows the initial announcement made on September 27, 2021. With all necessary regulatory approvals now obtained, Hikma is moving forward to close the transaction and will provide further updates upon completion.
Hikma Pharmaceuticals announced a $15 million investment from its venture capital arm, Hikma Ventures, in Activ Surgical, enhancing the Series B financing to a total of $60 million. Activ Surgical is developing AI-driven surgical technologies aimed at improving surgical outcomes. The ActivSight imaging module, which enhances visualization during surgery, has received FDA clearance and is set for broader availability in 2022. This investment will facilitate Activ Surgical's global launch, empowering surgeons with advanced decision-making tools and improving patient safety.
Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures, has led an $11 million financing round for NuvoAir, a digital health company focusing on chronic disease management and decentralized clinical trials, particularly for respiratory conditions like COPD and asthma. This investment extends NuvoAir's Series A funding to $25 million in total. The funds will be used to enhance NuvoAir's platform, grow its team, and expand clinical services globally.
Hikma Pharmaceuticals announced the acquisition of Teligent Inc.'s Canadian assets for $45.75 million, expected to close by Q1 2022. This deal includes a portfolio of 25 sterile injectable products and 3 ophthalmic products, with 7 additional products in the pipeline, enhancing Hikma's entry into the Canadian market. Riad Mishlawi highlighted the strategic importance of this expansion, leveraging their marketing expertise to strengthen their North American presence. Teligent is currently under Chapter 11 Bankruptcy protection, necessitating this asset sale.
Hikma Pharmaceuticals PLC has launched Hikma 503B, a new outsourced sterile compounding business aimed at providing high-quality, ready-to-administer injectable medications tailored for US healthcare providers. The US market for outsourced compounded sterile injectable medications is expected to exceed $2 billion annually. Hikma is the second-largest supplier of generic injectables in US hospitals. The new facility in Dayton, NJ, enhances their capacity to meet rising demand and will comply with FDA's CGMP standards. Hikma 503B is set to operate nationwide by the end of 2022.
Gedeon Richter and Hikma Pharmaceuticals announced an exclusive licensing agreement for the commercialization of denosumab biosimilars in the US, referencing Prolia and Xgeva. Richter will handle product development and supply, while Hikma will manage FDA registration and US commercialization. The agreement includes an upfront payment and milestone payments totaling a double-digit million USD figure. This collaboration aims to enhance treatment options in the US market for osteoporosis and bone metastasis.
Hikma Pharmaceuticals has announced a donation of 50,000 vials of Naloxone HCl Injection to the Opioid Safety and Naloxone Network (OSNN) Buyers Club, aiding in the critical shortage of this life-saving treatment for opioid overdoses in the US.
The donation originates from Hikma's sterile injectable manufacturing facility in Cherry Hill, NJ, and aligns with the company's Hikma Community Health initiative, focusing on addressing substance use disorder. Hikma aims to enhance access to naloxone amidst an ongoing overdose crisis.
